Antimicrobial susceptibilities of Vibrio cholerae strains isolated from cholera patients admitted to the Infectious Diseases Hospital, Calcutta, India for 6 years were analysed to determine the changing trends ; 840 V. cholerae strains isolated in 1992-1997 were included in this study. Among V. cholerae serogoup O1 and O139, ampicillin resistance increased from 1992 (35 and 70 %, respectively) to 1997 (both serogroups 100 %). Resistance to furazolidone and streptomycin was constantly high among V. cholerae O1 strains with gradual increase in resistance to other drugs such as ciprofloxacin, co-trimoxazole, neomycin and nalidixic acid. V. cholerae O139 strains exhibited susceptibilities to furazolidone and streptomycin comparable with those of O1 strains. However, after initial increase in resistance to chloramphenicol and co-trimoxazole, all the V. cholerae O139 strains became susceptible to these two drugs from 1995 onwards. Both V. cholerae O1 and O139 remained largely susceptible to gentamicin and tetracycline. V. cholerae non-O1, non-O139 strains, in contrast, exhibited high levels of resistance to virtually every class of antimicrobial agents tested in this study especially from 1995. Kruskal-Wallis one-way analysis showed that V. cholerae O1 Ogawa serogroup exhibited significant yearly increase in resistance to nine antibiotics followed by non-O1 non-O139 and O139 strains to six antibiotics and two antibiotics respectively. Interesting observation encountered in this study was the dissipation of some of the resistant patterns commonly found among V. cholerae non-O1 non-O139 or O1 serogroups to the O139 serogroup and ice ersa during the succeeding years.
INTRODUCTION
The definition of emerging infectious diseases in the Institution of Medicine report includes drug-resistance infections, which have been on the upsurge for the past several years [1] [2] [3] . Recent examples include multi drug resistance in Mycobacterium tuberculosis in USA [4] , Shigella dysenteriae type I infection in Africa [5] , Salmonella typhi in India [6] , and Vibrio cholerae in Ecuador [7] . Vibrio cholerae O1 and O139 serogroups are the well-known aetiologic agents of epidemic cholera. Less is reported about V. cholerae belonging to the non-O1 non-O139 serogroups, but their participation in causing cholera-like diarrhoea should not be under-estimated particularly after the emergence of O139 Bengal. Clinical laboratories do not always test for non-O1 non-O139 serogroups on a routine basis, both with respect to serotype and with respect to susceptibility to different classes of antimicrobial agents. It is important to ascertain the variations in resistance and to relate these variations to mechanisms of resistance. We have been monitoring different serogroups of V. cholerae among hospitalized cholera patients for the past several years in Calcutta, India [8] . The major objective of this study was to analyse the trends in multiple antibiotic resistance among clinical strains of V. cholerae isolated in 1992-7 in Calcutta.
METHODS

Vibrio cholerae strains
Eight hundred and forty strains of V. cholerae isolated between 1992 and 1997 from cholera and cholera-like patients admitted in the Infectious Diseases Hospital, Calcutta were included in this study. All the V. cholerae strains were isolated and identified by standard laboratory methods [9] , and further confirmed by serology using antisera prepared in our Institute. The 840 strains of V. cholerae strains included 326 V. cholerae O1 Ogawa, 314 V. cholerae O139 and 200 V. cholerae non-O1 non-O139 strains. All the strains were stored in nutrient agar stabs at room temperature (20-30 mC) and antibiotic susceptibility testing was performed at monthly intervals.
Antimicrobial susceptibility testing
Antimicrobial susceptibility analysis of V. cholerae was performed by the disk diffusion technique [10] , with commercial discs (Hi Media, Bombay, India). The following antibiotics were used, ampicillin (A, 10 mcg), chloramphenicol (C, 30 mcg), ciprofloxacin (Cf, 5 mcg), co-trimoxazole (Co, 25 mcg), furazolidone (Fz, 50 mcg), gentamicin (G, 10 mcg), nalidixic acid (Na, 30 mcg), neomycin (N, 30 mcg), norfloxacin (Nf, 10 mcg), streptomycin (S, 10 mcg) and tetracycline (T, 30 mcg). Characterisation of strains as susceptible, intermediately resistant, or resistant was based on the size of the inhibition zones according to the manufacturer's instructions, which matched the interpretive criteria recommended by the World Health Organization [11] . In this study, strains showing intermediate zones of growth inhibition were interpreted as resistant on the basis of previous MIC studies with V. cholerae [12] .
Statistical analysis
The data were entered into a data base software package  3.5 in a personal computer separately by two individuals and converted into - 6.1 as rec. file for matching data to derive the consistency and validity. The validated data were random checked and then compiled and analysed using the SPSS 4.0 version software package. For comparing the mean rank differences in resistance to each drug for each year, the duration of 6 years from 1992 to 1997 were divided into six groups each for V. cholerae O1, O139 and non-O1 non-O139 for all drugs. For nonparametric tests, Kruskal-Wallis one-way analysis of variance was employed to compare the mean rank differences in resistance to each drug for each year, 1992-7. A ' P ' value of 0n05 was considered statistically significant.
RESULTS
Results on the drug resistance of V. cholerae O1 strains are furnished in Table 1 . Increase in resistant to ampicillin, co-trimoxazole, nalidixic acid and neomycin was constantly recorded from 1994. Almost all the V. cholerae O1 strains were uniformly resistant to furazolidone and streptomycin throughout the study period. From low levels of resistance to chromphenicol in 1992 and 1993, 73 % were resistant to this drug in 1994 and in subsequent years showed a wavering trend (Table 1) . V. cholerae O1 strains were mostly susceptible to gentamicin and tetracycline. A perceptible increase in the isolation of ciprofloxacin and norfloxacin resistant strains was noticed from 1995.
Like V. cholerae O1, O139 strains were resistant to ampicillin, furazolidone and streptomycin and mostly susceptible to nalidixic acid, norfloxacin and tetracycline (Table 2) . Ciprofloxacin resistant V. cholerae O139 strains first appeared in 1995, but the isolation frequency was low. Frequency in the isolation of chloramphenicol and co-trimoxazole resistant strains of V. cholerae O139 was highest during 1994-5 and thereafter declined sharply in the succeeding years (Table 2) . Ampicillin, co-trimoxazole, furazolidone, neomycin and streptomycin resistant strains of V. cholerae non-O1 non-O139 strains were generally high between 1992 and 1997 as shown in Table 3 . In contrast to V. cholerae O1 and O139, the non-O1, non-O139 strains were more frequently resistant to ciprofloxacin, norfloxacin and tetracycline (Table 3) . To determine statistically the yearly increase in antibiotic resistance among V. cholerae strains isolated between 1992 and 1997, we used Kruskal-Wallis oneway analysis of variance and the results are depicted in Table 4 . Except for gentamicin and tetracycline, V. cholerae O1 strains were increasingly resistant to all the tested antibiotics. Among V. cholerae O139 strains, significant yearly increase in resistance was recorded only for ampicillin and neomycin. However, significant decrease in resistance was recorded among V. cholerae O139 to chloramphenicol, co-trimoxazole, nalidixic acid, and streptomycin. V. cholerae non-O1, non-O139 strains showed significant increase in resistance to most of the tested antibiotics such as ampicillin, chloramphenicol, ciprofloxacin, neomycin, nalidixic acid and norfloxacin.
One hundred and nineteen different multidrug resistance profiles were encountered in this study (data not shown). Two processes (emergence and dissemination) account for strains of antibiotic resistance in V. cholerae. It seems that antibiotic resistance characters confined to one serogroup for a particular period of time was presumably dissipated to the other V. cholerae serogroup(s), in which it became stable and then became dominant in the subsequent years. As shown in Table 5 , the profiles AFz and AFzN are recorded among V. cholerae non-O1 and non-O139 strains from 1992 and these profiles are respectively recorded among 17 % (12\71 strains) and 39n4 % (28\71 strains) of V. cholerae O139 in 1997. Similarly, the profile AFzNS was first recorded among V. cholerae O1 and non-O1 non-O139 strains from 1992 and most likely was transferred to 67n7% of O139 serogroup (42\64 strains), which was one of the dominant profiles in 1996. The profile ACoFzNaS was first recorded during 1993 among V. cholerae O139 and non-O1 and non-O139 strains followed by V. cholerae O1 strains from 1994 (4\74 strains), in which preponderance of this profile reached to 30 % (16\53 strains). AFzS profile was recorded first among V. cholerae O1 in 1992 followed by non-O1 and non-O139 strains until 1996. In 1997, this profile was dominantly found among 18n3% of V. cholerae O139 strains (13\71 strains).
DISCUSSION
Even though the therapy for cholera is principally supportive, antimicrobial therapy can be useful in decreasing the volume of stools and length of illness [13, 14] . While tetracycline has been the mainstay of therapy, chloramphenicol, furazolidone and co-trimoxazole are the other reported alternatives [15, 16] . Multidrug resistant classical V. cholerae strains and simultaneous epidemic outbreaks of both classical and ElTor biotypes of V. cholerae has been reported in Bangladesh [17] . Majority of the ElTor strains in this study was resistant to ampicillin and furazolidone and a similar trend is seen in Calcutta. Since cholera is a non-invasive disease, drugs such as co-trimoxazole, which is not absorbed from the gastrointestinal tract, was widely used for the treatment [18, 19] . Resistance of an ElTor strain of V. cholerae to trimethoprim, streptomycin and the vibriostatic agent O\129 (2,4-diamino-6,7-diisopropylpteridine) is due to a transposon inserted into the chromosome [20] , whose transfer is being enhanced by pretreatment with these drugs for which the markers encode resistance. This phenomenon may, in large part, be responsible for the rapid dissemination and high incidence of co-trimoxazole and streptomycin resistance among V. cholerae isolated from 1989 in Calcutta [21] . Almost all the V. cholerae O1 strains were resistant to co-trimoxazole versus none of V. cholerae O139 strains isolated during 1996-7 [22] . The higher incidence of V. cholerae non-O1, non-O139 strains resistant to tetracycline compared to O1 and O139 strains in this study could be a prelude to the possible emergence of tetracycline resistant strains of V. cholerae O1 and O139.
Reservation about promotion of ciprofloxacin as a first line drug for the treatment of cholera in developing countries has been expressed [23] , since it is an important substitute drug for treatment of multidrug resistant enteric and other pathogens. Extensive use of this drug and empirical therapy for treating diarrhoeal infection might have promoted incidence of ciprofloxacin resistant V. cholerae, which has emerged for the first time in Calcutta during 1992 among V. cholerae non-O1 non-O139 and during 1995 among V. cholerae O1 and O139 strains [24] .
Since tetracycline resistant V. cholerae O1 strains have been responsible for major epidemics of cholera in Latin America, Tanzania, Bangladesh and Zaire [7, [25] [26] [27] , norfloxacin is widely used as an alternative to tetracycline for the treatment. Even though the incidence level of norfloxacin resistant strains among V. cholerae O1 and O139 is less in the present study, the non-O1 non-O139 strains exhibited a higher level of incidence, especially during 1996-7.
Based on the chronological evidence gleaned from this study it appears that some of the drug resistance expression might have transferred from one serogroup of V. cholerae to the other. However, the possibility of acquiring antibiotic resistance by inter\intra generic transfer cannot be ignored. The major patterns of multiple antibiotic resistance determined in Calcutta are comparable with those from other endemic locals in India and Bangladesh. The antibiotic resistance profiles AFz ; AFzN and AFzNS encountered in this study were also reported common among V. cholerae O139 strains isolated from Madras, Nagpur [28] ; Dhaka, Bangladesh [29] ; Nagpur, Midnapur, Madras, Amravati [30] respectively. The profile ACoFzNaS was common among V. cholerae O1 strains isolated from Bhillai, Ahmadabad, Allephey, Madras, Vellore and Dibrugarh [31] .
Early studies conducted in India showed that the prevalence of multidrug resistant strains of V. cholerae non-O1 was a rare event [32, 33] . Sundaram & Murthy [34] reported that only 2n7 % non-O1 isolates were multi drug resistant in Madras ; an area endemic for cholera in south India, but none of the strains was resistant to nalidixic acid or furazolidone. In the current study, we have observed that like O1, non-O1 and non-O139 isolates exhibited resistance to furazolidone and nalidixic acid.
It is amply clear that long-term surveillance programmes are essential to identify changes in the spectrum of microbial pathogens causing serious infection and to monitor trends in antimicrobial resistance patterns [35] [36] [37] . The information gleaned from the surveillance efforts is integral to the designing approaches to the therapy of serious infection and also to defining appropriate control measures for antimicrobial-resistance pathogens.
